This filing appears to be a procedural step for listing additional securities on the ASX. Without details on the number of shares or purpose, the market impact is likely minimal. Monitor for subsequent filings that may disclose the size, pricing, or intended use of the newly quoted securities.
Price Chart
Executive Summary
Alterity Therapeutics filed a Form 6-K with an Exhibit 99.1 titled 'Application for quotation of securities - ATH'. The filing is a routine administrative step to list additional securities, likely on the ASX. No financial details, share amounts, or pricing were disclosed in the text, and the substantive exhibit is provided as an image that cannot be analyzed. The impact is neutral and minimal.
Key Facts
- Filed Form 6-K on July 9, 2026 for the month of July 2026.
- Exhibit 99.1 is an 'Application for quotation of securities - ATH'.
- The 6-K is incorporated by reference into several existing S-8 and F-3 registration statements.
- The filing contains no revenue, EPS, share count, or pricing information in the text.
- The substantive exhibit (ex_986165.htm) is an image file, preventing extraction of specific details.
Financial Impact
No financial data disclosed in the filing; impact is negligible without details on the size or terms of the securities application.
Risk Factors
- Potential dilution if the quotation relates to new shares issued in a future offering, but no details available.
- Lack of transparency on the number of securities or purpose creates uncertainty around capital structure changes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-023086 |
| Document: 0001437749-26-023086-index-headers.html | 0001437749-26-023086 |
| Document: 0001437749-26-023086-index.html | 0001437749-26-023086 |
| Document: 0001437749-26-023086.txt | 0001437749-26-023086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.14 (−2.39%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.14 (+2.39%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.14 (+2.39%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.14 (−10.46%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.14 (−10.46%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.14 (−11.93%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.14 (−31.41%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.14 (−33.54%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.14 (−33.54%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.14 (−41.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers